EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis

Chi-Hsien Huang iD, Shiow-Ing Wang, Frank S Fan, Hsueh-Ju Lu, James Cheng-Chung Wei iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2024

DOI: 10.1093/ehjcvp/pvae056 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Chi-Hsien Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine and Community Medicine, E-Da Hospital, I-Shou University, Kaohsiung City 824, Taiwan. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective in reducing cardiovascular events, but their impact on all-cause mortality and medical utilization compared to statins is unclear. This study investigated PCSK9 inhibitor use and its impact on mortality and medical utilization vs. statins, using TriNetX database data with up to 9 years of follow-up. Methods and results This retrospective cohort study analysed TriNetX data spanning 1 July 2015, to 31 December 2023, including 79 194 PCSK9 inhibitor users (alirocumab, evolocumab, inclisiran) and 5 437 513 statin users with hyperlipidaemia. The primary outcomes were all-cause mortality and medical utilization, including hospital inpatient services, emergency department visits, critical care, and mechanical ventilation. Propensity score matching showed that PCSK9 inhibitor use was associated with a 28.3% lower risk of all-cause mortality [adjusted hazard ratio (aHR) 0.717, 95% confidence interval (CI): 0.673–0.763] and significant reductions in medical utilization (hospital inpatient services usage: aHR 0.692, 95% CI: 0.664–0.721; emergency department services: aHR 0.756, 95% CI: 0.726–0.788; critical care services: aHR 0.619, 95% CI: 0.578–0.664; and mechanical ventilation: aHR 0.537, 95% CI: 0.484–0.596) compared to statins. These findings were consistent across various demographics and clinical subgroups. The sensitivity analyses supported the robustness of the findings.

Conclusion

PCSK9 inhibitors significantly reduced all-cause mortality and medical utilization compared to statins, suggesting their important role in dyslipidaemia management, particularly for statin-naïve or intolerant patients. Further research, including randomized controlled trials, is needed to confirm these findings and explore the underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsHumansRetrospective StudiesMaleFemaleAgedMiddle AgedTreatment OutcomeRisk FactorsTime FactorsRisk AssessmentHyperlipidemiasDatabases, FactualCause of DeathSerine Proteinase InhibitorsBiomarkersDyslipidemiasAntibodies, Monoclonal, HumanizedProprotein Convertase 9

Stichwörter der Autor:innen

All-cause mortalityMedical utilizationPCSK9 inhibitorsStatins

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsSerine Proteinase InhibitorsBiomarkersevolocumabAntibodies, Monoclonal, HumanizedProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Family Medicine and Community Medicine, E-Da Hospital, I-Shou University, Kaohsiung City 824, Taiwan.
  • College of Medicine, I-Shou University, Kaohsiung City 824, Taiwan.
  • Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
  • Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.

ORCID-Profile: Chi-Hsien Huang, James Cheng-Chung Wei

Förderung

  • National Science and Technology Council

Zitieren

APA

Huang, C. H., Wang, S. I., Fan, F. S., Lu, H. J., & Wei, J. C. (2024). Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae056

Vancouver

Huang CH, Wang SI, Fan FS, Lu HJ, Wei JC. Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae056

BibTeX
@article{Huang2024,
  author = {Huang, Chi-Hsien and Wang, Shiow-Ing and Fan, Frank S and Lu, Hsueh-Ju and Wei, James Cheng-Chung},
  title = {Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae056}
}
Kostenlos starten →